Analyzing MRNA Stock Performance – A Market Overview

By Scott Lee • Friday, October 31 10:14 • Permanent Link

Moderna logged a -2.4% change during today's morning session, and is now trading at a price of $27.48 per share. The S&P 500 index moved 0.0%. MRNA's trading volume is 3,500,498 compared to the stock's average volume of 10,836,228.

Moderna trades -31.82% away from its average analyst target price of $40.3 per share. The 20 analysts following the stock have set target prices ranging from $12.0 to $178.0, and on average have given Moderna a rating of hold.

If you are considering an investment in MRNA, you'll want to know the following:

Moderna has moved -48.5% over the last year, and the S&P 500 logged a change of 19.1%
Based on its trailing earnings per share of -7.51, Moderna has a trailing 12 month Price to Earnings (P/E) ratio of -3.7 while the S&P 500 average is 29.3
MRNA has a forward P/E ratio of -3.2 based on its forward 12 month price to earnings (EPS) of $-8.7 per share
Its Price to Book (P/B) ratio is 1.14 compared to its sector average of 3.19
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Based in Cambridge, the company has 5,800 full time employees and a market cap of $10.73 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.